
MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
Location: Foster City, in-office | Duration: 8-12 weeks
Mirum Pharmaceuticals is a growing rare-disease biopharmaceutical company focused on transforming the lives of patients with cholestatic liver diseases. Mirum is advancing several programs globally, including volixibat, LIVMARLI® (maralixibat), MRM-3379 and BJT-778 in different rare diseases.
We are offering a unique opportunity for a motivated, analytical, and scientifically curious individual to join our Global Clinical Operations Team in Foster City, CA. This short-term internship will contribute to ongoing clinical programs and strategic evidence generation supporting Mirum’s next-generation therapies in rare diseases.
The selected intern will work closely with Clinical Operations to review study related document and the trial master file to ensure completeness and accuracy. Additionally, the selected individual will work closely with the clinical operation’s lead to review data listings, create trackers and manage samples to ensure completeness and accuracy.
JOB FUNCTIONS/RESPONSIBILITIES
QUALIFICATIONS
Education/Experience
PREFERRED QUALIFICATIONS
Application needs to include a CV
During this internship you will contribute meaningfully to data interpretation, data review and evidence generation activities working alongside an agile and passionate team that values curiosity, precision, and impact. Let’s learn, get things done, and have fun seriously!
Please include your cover letter with your application describing your qualifications and reasoning for wanting this internship. The pay for this role will be in the $35-45/hr range.
#LI-ONSITE
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.